Sanofi has discontinued clinical development of amlitelimab, an OX40 inhibitor, for the treatment of moderate to severe atopic dermatitis, citing a lack of meaningful additional benefits for patients, according to a press release.
Based on a strategic assessment of the pipeline, the company decided it will not submit amlitelimab (SAR445229) for global regulatory review, according to the release.
“Sanofi has determined that the totality of efficacy and safety evidence generated to date does not support further development of amlitelimab in AD,” the company stated in the release. “While the

Effective leadership is more than just solving problems.
Prioritizing a growth mindset and developing self-awareness can help ophthalmologists achieve a leadership style that supports other people without simply focusing on efficiency, according to Kathryn Colby, MD, PhD, chair of the department of ophthalmology at NYU Grossman School of Medicine.
{{VIDEO}}
“We're all surgeons; how do we fix problems? We diagnose and we treat them. The big lesson I learned from my first chairmanship is that that doesn't work with people,” Colby said in this episode of Steeped Insights, a video blog series

Symptom recognition and management of heart failure during the peripartum period remains a significant barrier in cardio-obstetric care, researchers reported.
As a result, on behalf of the American Heart Association Women’s Health Science Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; and Council on Cardiovascular and Stroke Nursing, Demilade A. Adedinsewo, MB, ChB, director of research for the Women’s Heart Clinic at Mayo Clinic in Jacksonville, Florida, and colleagues wrote a scientific statement addressing challenges and

The FDA has approved a second blood-based colorectal cancer screening option for adults aged 45 years and older at average risk for the disease.
SimpleScreen CRC (Freenome) is a noninvasive test that assesses cell-free DNA in a blood sample to detect signals associated with CRC. A positive result suggests CRC or advanced precancerous lesions and should be followed by colonoscopy, according to a manufacturer press release.
An estimated 60 million people eligible for screening in the U.S. are overdue, despite CRC being the second-leading cause of cancer-related deaths.
“The fact is that 90% of

A 37-year-old right-hand dominant concrete contractor with no significant medical history presented to the outpatient orthopedic clinic for evaluation of left shoulder pain after an acute injury.
He sustained an acute shoulder injury while wrestling with his brother 6 days before clinical presentation. Three days after the injury, he presented to the ED for initial evaluation where three-view radiographs of the left shoulder revealed a closed, isolated left greater tuberosity fracture with approximately 9 mm of displacement without glenohumeral dislocation. He was placed in a sling and

Disruptions to funding and new policies aimed at aligning foreign aid programs with the Trump administration’s agenda have had a broad and negative impact on a critical global HIV/AIDS treatment program, new research showed.
According to survey responses from more than 160 facilities in dozens of countries, 77% of implementing partners of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) said the administration asked them to restrict certain work “to comply with U.S. policy” and the same proportion said they stopped providing at least one HIV services to key populations, Jennifer

Children with growth hormone deficiency had a reduction in treatment-related adverse events over time and nearly reached a height standard deviation score of 0 with once-weekly somatrogon-ghla, according to long-term study data.
As Healio previously reported, the FDA approved somatrogon-ghla (Ngenla, Opko Health/Pfizer) for children with growth failure due to inadequate secretion of endogenous GH in June 2023. The approval came after a phase 3 trial found the once-weekly therapy conferred noninferior improvements in annualized height velocity compared with somatropin (Genotropin, Pfizer). In

With support from a 5-year, $7.2 million NIH grant, researchers at the Icahn School of Medicine at Mount Sinai are creating an Asthma and Allergic Diseases Cooperative Research Center, according to a press release.
The release outlined that “advancing personalized treatment strategies for peanut allergy” via research on biological mechanisms and biomarkers is the focus of the Immunologic Trajectories of Peanut Desensitization (INROADS) multidisciplinary research center.
Supinda Bunyavanich, MD, MPH, MPhil, is the contact principal investigator of INROADS, and Scott H. Sicherer, MD, FAAP, is the

When Moffitt Cancer Center nurses sought to put women about to start breast cancer treatment at ease, they looked to the heavens — in a way, at least — for inspiration.
A sensory experience in which twinkling stars and drifting clouds are projected on a dark wall led to sustained reductions in anxiety among patients visiting the center for their first chemotherapy or immunotherapy infusion, results of a pilot study showed.
The research effort’s success led to the creation of a new Starlight Wellness Room, which opened this summer on Moffitt’s McKinley campus in Tampa, Florida.
All patients with

Patients who were prescribed GLP-1 receptor agonists for type 2 diabetes demonstrated increased risks for psoriatic arthritis, psoriasis and autoimmune thyroiditis vs. those treated with dipeptidyl peptidase-4 inhibitors, according to data.
However, the researchers, who published their findings in ACR Open Rheumatology, additionally found that GLP-1 drugs for diabetes were associated with lower risks for dermatomyositis and bullous pemphigoid, compared with dipeptidyl peptidase-4 (DPP-4) inhibition.
“As GLP-1 receptor agonists and other antidiabetic agents become more widely used, understanding